The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Emergent ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 27, 2021 / Schall Law Firm, a national shareholder rights law firm, is reminding investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. (“Acadia” or “the Company”) (NASDAQ: ACAD) for violating Sections 10 (b) and 20 (a) of the Securities Exchange Act of 1934 and Rule 10b-5 issued by the Securities and Exchange Commission.

Investors who purchased the Company’s securities between June 15, 2020 and April 4, 2021 (including the “Class Period”) are requested to contact the Company before June 18, 2021.

If you are a shareholder who has suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall law firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights at no charge. You can also contact us on the company’s website at www.schallfirm.com or by email at brian@schallfirm.com.

In this case, the class has not yet been certified and you will not be represented by a lawyer until certification. If you don’t take action, you can remain an absent class member.

According to the complaint, the company made false and misleading statements to the market. Acadia filed an sNDA with the FDA for pimavanserin, which was suffering from design and statistical issues. The pimavanserin sNDA contained no endorsement for its approval, despite the company making it known to investors. As a result, the FDA was unlikely to approve the submitted sNDA. Because of these facts, the company’s public statements were false and materially misleading throughout the teaching period. When the market learned the truth about Acadia, investors suffered damage.

Join the case to make up for your losses.

Schall law firm represents investors around the world and specializes in class action and shareholder disputes.

The story goes on

This press release may be viewed as a solicitor’s advertisement in some jurisdictions under applicable laws and ethical rules.

CONTACT:
The law firm Schall
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The law firm Schall

View source version on accesswire.com:
https://www.accesswire.com/649482/INVESTOR-ACTION-NOTICE-The-Schall-Law-Firm-Reminds-Investors-of-a-Class-Action-Lawsuit-Against-Emergent-ACADIA-Pharmaceuticals-Inc- and-encourages-investors-with-losses-in-excess-100,000-to-contact-the-company

Comments are closed.